Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many claims are broadly consistent with the label excerpts (lipid lowering, HDL/LDL/TG changes, and cardiovascular risk reduction; pediatric age range 10–17; mechanism as HMG-CoA reductase inhibition; general dosing range). However, several claims are not supported or are only partially supported by the provided excerpts, including specific quantitative LDL reduction by dose and several specific safety/cessation/side-effect claims (memory complaints, common muscle/liver enzyme/digestive issues, and diabetes/memory associations), which are not directly substantiated in the supplied label text.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication.
Label describes LIPITOR as a statin (HMG-CoA reductase inhibitor) in Section 12.1 and references statins in Sections 5 and 7.
Lipitor is prescribed to lower LDL cholesterol.
Section 1.2 and Section 12.1: reduces LDL-C (and other lipids).
Lipitor is prescribed to lower triglycerides.
Section 1.2: adjunct to diet to reduce elevated TG; Section 12.1: reduces TG.
Lipitor raises HDL.
Section 1.2: increases HDL-C; Section 14.2: increases HDL-C.
Lipitor reduces the risk of heart attack.
Section 1.1: reduces risk of myocardial infarction.
Lipitor reduces the risk of stroke.
Section 1.1: reduces risk of stroke (including fatal and non-fatal stroke).
Lipitor reduces the risk of other cardiovascular events.
Section 1.1 includes reduction in revascularization procedures and angina; Section 14.1 includes major cardiovascular events.
Lipitor is used in adults and children over 10 with high cholesterol.
Section 1.2 pediatric indication for ages 10–17 with heterozygous familial hypercholesterolemia; adult indication for hypercholesterolemia exists in Sections 1 and 2.
Lipitor is used in adults and children over 10 with mixed dyslipidemia.
Section 1.2 indicates mixed dyslipidemia (adult). Pediatric excerpt provided is specifically for heterozygous familial hypercholesterolemia; adult mixed dyslipidemia is supported.
Lipitor is used to treat hyperlipidemia.
Section 1.2: indications for hypercholesterolemia and mixed dyslipidemia (lipid-altering therapy).
Lipitor works by blocking HMG-CoA reductase.
Section 12.1: selective, competitive inhibitor of HMG-CoA reductase.
HMG-CoA reductase is the enzyme responsible for making cholesterol in the liver.
Not explicitly stated in provided excerpts; however Section 12.1 identifies it as the target enzyme inhibited by LIPITOR. (Partial support at best; no explicit 'in liver' statement in excerpt.)
Lipitor reduces plaque buildup in arteries.
Section 12.1: mentions elevated lipoproteins promote atherosclerosis; LIPITOR reduces LDL-C and apo B. (No explicit 'plaque buildup' wording in provided excerpts; support is indirect.)
Lipitor cuts cardiovascular risk.
Section 1.1 and Section 14.1: reduces coronary events/major cardiovascular events and stroke/MI and revascularization.
Lipitor cuts cardiovascular risk especially in people with diabetes.
Section 1.1: in patients with type 2 diabetes without clinically evident CHD but with multiple risk factors, indicated to reduce risk of MI and stroke.
Lipitor cuts cardiovascular risk especially in people with hypertension.
Section 1.1: multiple risk factors include hypertension; indicated for reduction of MI/stroke/revascularization/angina in adults with multiple risk factors.
Lipitor cuts cardiovascular risk especially in people with a family history of heart disease.
Section 1.1: multiple risk factors include family history of early coronary heart disease.
Lipitor is a moderate-to-high intensity statin.
Not supported by the provided excerpts (no intensity categorization present).
The original Lipitor patent expired in 2011.
Not supported by provided label excerpts.
Since 2011, generic atorvastatin is widely available.
Not supported by provided label excerpts.
Patients commonly report muscle pain as a side effect of Lipitor.
Partially supported: Section 6.1 lists myalgia (0.7%) among common adverse reactions leading to discontinuation, but 'commonly report' and 'muscle pain' wording are not directly quantified for incidence at/above 2%.
High-dose Lipitor is linked to a higher incidence of new-onset diabetes.
Not supported by provided excerpts (no diabetes/new-onset diabetes statement in provided label text).
Stopping Lipitor can cause rising LDL within weeks.
Not supported by provided excerpts (no discontinuation/rebound kinetics described).
Unsupported Statements
Lipitor lowers LDL by 20-55% depending on dose.
No quantitative LDL reduction range by dose is present in the provided excerpts (Section 14.2 describes timeline but not the 20–55% range).
Lipitor raises HDL.
Supported by label, but this item appears also in 'accurateStatements' with support; no issue. (No action.)
Lipitor is a moderate-to-high intensity statin.
No 'intensity' categorization is included in the provided label excerpts.
The original Lipitor patent expired in 2011.
Not contained in the provided label excerpts.
Since 2011, generic atorvastatin is widely available.
Not contained in the provided label excerpts.
Patients commonly report liver enzyme elevation as a side effect of Lipitor.
Label excerpt lists alanine aminotransferase increase (0.4%) as a common discontinuation reason, but does not support the phrasing 'commonly report' liver enzyme elevation as a general side effect incidence.
Patients commonly report digestive issues as a side effect of Lipitor.
Label excerpt lists diarrhea (0.5% discontinuation reason; 6.8% as most commonly reported adverse reaction) and nausea (0.4%). It does not support 'digestive issues' as a broad commonly reported category beyond those specific terms.
High-dose Lipitor is linked to memory complaints.
The excerpt lists 'memory impairment' in postmarketing experience, but does not link this to high dose specifically.
Stopping Lipitor abruptly can cause cholesterol to rebound quickly.
No discontinuation/rebound statement is included in the provided excerpts.
Rising LDL after stopping Lipitor can increase cardiovascular risk.
No statement about post-discontinuation LDL rise or resulting cardiovascular risk is included in the provided excerpts.
HMG-CoA reductase is the enzyme responsible for making cholesterol in the liver.
The provided excerpt identifies HMG-CoA reductase as the inhibited enzyme, but does not explicitly state 'responsible for making cholesterol in the liver.'
Lipitor reduces plaque buildup in arteries.
The provided excerpt discusses atherosclerosis and lipid reductions but does not explicitly state 'plaque buildup' wording.
Contradictions
Important Omissions
Boxed warnings: pregnancy contraindication is present in the provided excerpts as a contraindication, but no pregnancy-risk discontinuation language was included in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several AI statements about side effects and high-dose risks (new-onset diabetes; memory complaints linked to high dose) and discontinuation rebound effects are not supported by the supplied label excerpts, which could misinform safety expectations. However, no explicit dosing contraindication conflicts were identified within the provided label-check scope.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported by the provided FDA label excerpts (e.g., LDL percentage range by dose, patent/generic availability, 'moderate-to-high intensity' categorization, high-dose diabetes/memory linkage, and discontinuation rebound effects).
Suggested Improvement
Restrict statements to those explicitly supported in the provided label excerpts (Sections 1.1/1.2, 2.1/2.2/2.4 as applicable, 12.1, 14.1/14.2, 5.1/5.2/5.5, 6.1/6.2, and 7). Remove or rephrase unsupported quantitative and causality/discontinuation-linked claims unless the exact label language is provided.